Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Topical agents for dermatological applications

a dermatological and topical agent technology, applied in the field of dermatological applications, can solve the problems of cosmetic skin improvement and hair growth, not speeding up the healing process, and having a negative effect on the quality of li

Active Publication Date: 2022-04-07
GENESIS MOLECULAR TECH INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most current medications for wounds, ulcers, burns, and skin diseases or disorders, however, merely focus on relief of the symptoms (e.g., inflammation), failing to target and address the underlying cause of the problem (see, e.g., Okur, M. E., et al., Asian J Pharm Sci. 2020; 10:661-684), and, therefore, do not speed the healing process.
Similar challenges exist for cosmetic skin improvement and hair growth.
For example, skin is the most visible reflection of human health and vitality, and wrinkles are an early sign of aging, which can have a negative effect on quality of life.
Although Botox is one of the most common wrinkles treatments, it does not heal the skin and its use to reduce wrinkles must be under strict control due to its high toxicity (Benedetto, A. V., Clinics in dermatology.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Topical agents for dermatological applications
  • Topical agents for dermatological applications
  • Topical agents for dermatological applications

Examples

Experimental program
Comparison scheme
Effect test

working examples

[0105]An illustration of the preparation of exemplary compounds of the present invention is provided in the representative Examples and Schemes below, wherein specific non-limiting examples of compounds are intended to illustrate particular embodiments of the present invention, and are not intended to limit the scope of the specification or the claims in any way. The compounds of the present invention may be prepared by the synthetic sequence shown in the non-limiting Examples and Schemes below. A skilled artisan will appreciate that other routes of synthesis may be employed as well. In particular, other routes of synthesis may in fact be applied to certain aspects of the present invention. For example, (R)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-(tert-butyldimethylsilyloxy)butanoic acid can be prepared according to Step 1-2 of Example 3, and used for the synthesis of compound 2. The skilled artisan is referred to general textbooks, such as March's Advanced Organic Chemistry (...

example 1

[0106](Reagents, synthetic methods, and biological characterization assays used) Unless otherwise noted, all reagents, starting materials and solvents were obtained from commercial suppliers and used without further purification. Concentration or evaporation refers to evaporation under vacuum using a Buchi rotatory evaporator.

[0107]Reaction products were purified by silica-gel chromatography with the solvent system indicated, or by HPLC purification using a C18 reverse phase semi-preparative HPLC column with solvent A (0.1% of TFA in water) and solvent B (0.1% of TFA in CH3CN) as eluents. All final products have at least 95% purity as determined by analytical HPLC analysis with UV detection at 210 nm and / or 254 nm. Reported yields are isolated yields.

[0108]Analytical HPLC analysis was performed on an Agilent 1100 HPLC with a Phenomenex Luna C18 (2) column (3 micron, 150×4.6 mm id) at a flow rate of 0.6 mL / min, eluting with a binary solvent system A and B using a 35%-70% B in 20 min ...

example 2

(Synthesis of (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N-(naphthalen-1-ylmethyl)propanamide (1))

[0113]Compound 1 was prepared according to the procedures disclosed in U.S. Pat. No. 7,671,054, as shown in Scheme 1, starting from 1-naphthaldehyde. The title compound 1 as a colorless oil. MS (ESI): m / z 493.3 (M+H)+; analytical HPLC: 15.3 min.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
flow rateaaaaaaaaaa
temperatureaaaaaaaaaa
elasticityaaaaaaaaaa
Login to View More

Abstract

Provided are compounds of formula (I), (Ia), (Ib), and (Ic), and pharmaceutically and / or cosmeceutically acceptable salts thereof. Additionally provided are pharmaceutical and / or cosmeceutical compositions and formulations, comprising the compounds and / or salts thereof, therapeutic and / or cosmetic methods using same for modulating (e.g., inhibiting) CREB binding protein (CBP) / β-catenin mediated signaling in treating skin related diseases, conditions or disorders (e.g., dermatitis, psoriasis, scarring, alopecia, etc.) mediated by aberrant CBP / β-catenin signaling, and cosmetic methods for treating skin conditions (e.g., aging, etc.) mediated by aberrant CBP / β-catenin signaling.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 087,670, filed Oct. 5, 2020, which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention relates generally to modulation of the Wnt / β-catenin pathway in mammalian (both human and non-human) cells and tissues, and more particularly to novel CREB binding protein (CBP) / β-catenin inhibitors and prodrugs thereof, cosmetic, and therapeutic uses thereof (e.g., in dermatological applications), and methods of making the disclosed exemplary compounds.BACKGROUND OF THE INVENTION[0003]Skin is the largest organ of human body, and along with hair and nails, skin acts as a boundary between the body and the external environment, protecting the body against pathogens and excessive water loss. Skin is also critical for insulation, temperature regulation, sensation, and the synthesis of molecules such as vitamin D. Ski...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D487/04A61K8/49A61Q19/00
CPCC07D487/04A61Q19/00A61K8/4953A61Q19/08A61Q7/00
Inventor RUAN, FUQIANG
Owner GENESIS MOLECULAR TECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com